ArticleLangenbeck's archives of surgery2025
Predictors of long-term survival outcomes of patients with hepatocellular carcinoma without recurrence at five years after liver resection.
Article in Langenbeck's archives of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeHepatocellular carcinoma (HCC) is an aggressive tumor. Few studies have reported predictors of long-term survival of patients without recurrence at five years after liver resection (LR).
methodsWe consecutively included 1133 patients with HCC undergoing LR. We excluded patients who developed recurrence or died within five years after LR (n = 639) and patients who were recurrence-free within a follow-up period of < 5 years (n = 243). The remaining 251 patients who were without recurrence at five years after LR were included in this study.
resultsSixty (23.9%) patients developed recurrence during the follow-up period, of whom, 51 (85%) showed recurrence within Milan criteria and 43 (71.7%) underwent curative treatments. Overall survival (OS) was not significantly different between patients with and those without recurrence (p = 0.63). The 10-year OS of the cohort was 78%; 10-year recurrence-free survival (RFS) was 68%. Multivariate analysis showed that MELD score per one increase (HR = 1.058; 95% CI = 1.005-1.115; p = 0.033) and age > 65 years (HR = 2.997; 95% CI = 1.543-5.820; p = 0.001) were associated with mortality, whereas no baseline variable was associated with recurrence.
conclusionsOlder age and higher MELD score were associated with mortality but no baseline variable was associated with recurrence in this cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.